From the Editor

Vaccine Nationalism Escalating Risk

June 02, 2023

Vaccine nationalism strengthens viruses and poses deadly risks for all involved.

Springing Forward

May 02, 2023

INTERPHEX was back in full swing with Keynote sessions highlighting cutting-edge technologies that are setting the stage for the bio/pharma industry’s future.

On Strike!

May 02, 2023

Strike action is impacting numerous sectors across Europe, including the bio/pharma industry.

Zauberkugel: Pfizer’s Seagen Acquisition

April 02, 2023

What can we take away from Pfifzer's acquisition of Seagen?

Legislative Hold-Up

April 02, 2023

A further setback to the publication of the pharmaceutical legislative changes in Europe may mean time is running out for appropriate review before 2024 parliamentary elections.

Feeling the Pinch

March 02, 2023

Soaring energy costs are compounding the challenges currently being faced by the European bio/pharma industry.

Improving Gender Diversity

February 02, 2023

Although some headway is being made into more gender-diverse executive levels in pharma, much more work is still needed.

The Commercial Message mRNA Products Send

February 02, 2023

This new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns.

Pedestrians as Priority

January 02, 2023

Coverage of COVID-19 vaccines was surprisingly displaced by this year’s astounding oncology and iconoclastic gene therapy “cures.”

Getting Personal for Blockbusters in 2023

January 02, 2023

The latest report from Clarivate has been published, highlighting 15 potential blockbusters to watch out for in 2023, the majority of which are personalized medicines.